CardioExchange Archive

December 23rd, 2010

John Mandrola: Looking Back at 2010 and Ahead to 2011

John Mandrola, MD, FACC

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and to make 3 predictions for 2011. Looking back at 2010: 1. By far, the number one heart story of 2010 was the release of the novel blood-thinning drug, dabigatran (Pradaxa), for the prevention […]

---

December 22nd, 2010

John Ryan: Looking Back at 2010 and Ahead to 2011

John Ryan, MD

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and to make 3 predictions for 2011. Looking back at 2010: 1. Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment: Ten years after the initial decoding of the human genome, we felt […]

---

December 22nd, 2010

Deepak Bhatt: Looking Back at 2010 and Ahead to 2011

Deepak L. Bhatt, MD, MPH

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and to make 3 predictions for 2011. Looking back at 2010: 1. PARTNER: Transcatheter aortic valve implantation significantly improved symptoms and reduced mortality in patients with severe aortic stenosis who were not candidates […]

---

December 21st, 2010

Rick Lange & David Hillis: Looking Back at 2010 and Ahead to 2011

Richard A. Lange, MD, MBA and L. David Hillis, MD

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and to make 3 predictions for 2011. Looking back at 2010: 1. Stenting Versus Endarterectomy for Carotid-Artery Stenosis: In patients with carotid artery stenoses, stenting and endarterectomy were associated with similar rates of […]

---

December 21st, 2010

Say Hello to Your New Drug Rep?

Micah Eimer, MD

Most of the doctors I know have, at one time or another, responded to a web-based “survey”. While I have tried not to make a second career out of it, I will admit that I have on occasion done a survey in between patients, at lunch, or at the end of the day.  They usually take 5 to 40 minutes […]

---

December 21st, 2010

Roger Blumenthal: Looking Back at 2010 and Ahead to 2011

Roger Blumenthal, M.D.

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and  to make 3 predictions for 2011. Looking back at 2010: Dabigatran etexilate approved to prevent stroke in atrial fibrillation. Several studies have shown that even good Coumadin clinics keep the INRs of […]

---

December 20th, 2010

JoAnne Foody: Looking Back at 2010 and Ahead to 2011

JoAnne M. Foody, MD

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and to make 3 predictions for 2011. Looking back at 2010: 1. The ACCORD lipid trial investigated the effects of adding fenofibrate to a statin (simvastatin) in 5518 patients with type 2 diabetes […]

---

December 20th, 2010

Steve Nissen: Looking Back at 2010 and Ahead to 2011

Steven E Nissen , MD

To celebrate the holiday season, CardioExchange asked several of our contributors to choose the 3 most important cardiology-related events of the past year and  to make 3 predictions for 2011.  Here is the first installment in the series. Looking back at 2010: 1. On September 23, the European Medicines Agency withdrew rosiglitazone from the market […]

---

December 17th, 2010

FDA Delays Approval of Ticagrelor

Larry Husten, PHD

Despite widespread expectations of an easy approval, the FDA has issued a complete response letter to AstraZeneca for Brilinta (ticagrelor). According to a press release from the company, the FDA has asked for additional analyses of data from the pivotal PLATO trial, but did not request any additional studies. AstraZeneca said it is evaluating the […]

---

December 15th, 2010

Heart Disease and Stroke in 2011: Mortality Continues to Decline, but Overall Burden Remains High

Larry Husten, PHD

From 1997 to 2007, the death rate from heart disease declined 27.8% and the death rate from stroke declined 44.8%. But inpatient cardiovascular operations and procedures increased during the same period by 27%, and heart disease and stroke cost $286 billion in 2007, more than any other diagnostic group. These are some of the most […]

---